CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 1, 2006, Pages 51-60

  Meur, Yannick Le ^a   Djebli, Nassim ^a   Szelag, Jean Christophe ^a   Hoizey, Guillaume ^a   Toupance, Olivier ^a   Rérolle, Jean Philippe ^a   Marquet, Pierre ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

32 DESMETHOXYSIROLIMUS; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYTOCHROME P450 3A5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HOMOZYGOSITY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; PHARMACOGENOMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; TANDEM MASS SPECTROMETRY; BIOAVAILABILITY; BLOOD; GENETICS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHARMACOGENETICS;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOPHENOLIC ACID; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIROLIMUS;

EID: 33745344584     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.03.012     Document Type: Article

References (29)

1. Sehgal S.N. Sirolimus: a new immunosuppressive agent: a historical perspective and immunosuppressive profile. In: Lieberman R., and Mukherjee A. (Eds). Principles of drug development in transplantation and autoimmunity (1996), RG Landes, Austin (TX) 271-282
2. Brattstrom C., Wilczek H., and Tyden G. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65 (1998) 1272-1274
3. Hong J.C., and Kahan B.D. Sirolimus-induced thrombocytopenia and leucopenia in renal transplant recipients. risk factors, incidence, progression and management. Transplantation 69 (2000) 2085-2090
4. Sattler M., Guengerich F.P., Yun C.H., Christians U., and Sewing K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20 (1992) 753-761
5. Cholerton S., Daly A.K., and Idle J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13 (1992) 434-439
6. Thummel K.E., and Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38 (1998) 389-430
7. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 (2001) 773-779
8. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., and Watkins P.B. The human CYP3A subfamily. practical considerations. Drug Metab Rev 32 (2000) 339-361
9. Haehner B.D., Gorski J.C., Vandenbranden M., Wrighton S.A., Janardan S.K., Watkins P.B., et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50 (1996) 52-59
10. Jounaidi Y., Hyrailles V., Gervot L., and Maurel P. Detection of CYP3A5 allelic variant. a candidate for the polymorphic expression of the protein?. Biochem Biophys Res Commun 22 (1996) 466-470
11. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
12. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 (2002) 162-172
13. van Schaik R.H.N., van der Heiden I.P., van den Anker J.N., and Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48 (2002) 1668-1671
14. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., and Ruterbories K. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 62 (2002) 162-172
15. Anglicheau D., Le Corre D., Lechaton S., Laurent-Puig P., Kreis H., Beaune P., et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 5 (2005) 595-603
16. Holt D.W., Lee T., Jones K., and Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 46 (2000) 1179-1183
17. Cattaneo D., Merlini S., Pellegrino M., Carrara F., Zenoni S., Murgia S., et al. Therapeutic drug monitoring of sirolimus. effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 4 (2004) 1345-1351
18. MacPhee I.A.M., Fredericks S., Tai T., Syrris P., Carter N.D., Johnston A., et al. Tacrolimus pharmacogenetics. polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486-1489
19. Hesselink D.A., van Schaik R.H.N., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245-254
20. Haufroid V., Mourad M., Van Kerchhove V., Wawrzyniak J., De Meyer M., Eddour D.C., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147-154
21. MacPhee I.A.M., Fredericks S., Mohamed M., Moreton M., Carter N.D., Johnston A., et al. Tacrolimus pharmacogenetics. the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians. Transplantation 79 (2005) 499-502
22. Zhao Y., Song M., Guan D., Bi S., Meng J., Li Q., et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 37 (2005) 178-181
23. Tsuchiya N., Satoh S., Tada H., Li Z., Ohyama C., Sato K., et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78 (2004) 1182-1187
24. Zheng H., Zeevi A., Schuetz E., Lamba J., McCurry K., Griffith B., et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44 (2004) 135-140
25. Thervet E., Anglicheau D., King B., Schlageter M.H., Cassinat B., Beaune P., et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76 (2003) 1233-1235
26. Goto M., Masuda S., Kiuchi T., Ogura Y., Oike F., Okuda M., et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14 (2004) 471-478
27. Anglicheau D., Thervet E., Etienne I., Hurault De Ligny B., Le Meur Y., Touchard G., et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75 (2004) 422-433
28. Min D.I., Ellingrod V.L., Marsh S., and McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 26 (2004) 524-528
29. Evans E., and Relling M.V. Moving towards individualized medicine with pharmacogenetics. Nature 429 (2004) 464-468